Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Work In Process: 2023-2025

Historic Work In Process for Tarsus Pharmaceuticals (TARS) over the last 2 years, with Sep 2025 value amounting to $1.0 million.

  • Tarsus Pharmaceuticals' Work In Process fell 37.12% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 37.12%. This contributed to the annual value of $614,000 for FY2024, which is 56.63% up from last year.
  • Tarsus Pharmaceuticals' Work In Process amounted to $1.0 million in Q3 2025, which was down 36.73% from $1.6 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Work In Process' 5-year high stood at $1.6 million during Q3 2024, with a 5-year trough of $392,000 in Q4 2023.
  • Its 3-year average for Work In Process is $977,125, with a median of $882,500 in 2025.
  • Its Work In Process has fluctuated over the past 5 years, first soared by 56.63% in 2024, then tumbled by 37.12% in 2025.
  • Tarsus Pharmaceuticals' Work In Process (Quarterly) stood at $392,000 in 2023, then skyrocketed by 56.63% to $614,000 in 2024, then slumped by 37.12% to $1.0 million in 2025.
  • Its Work In Process stands at $1.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $764,000 for Q1 2025.